Cytek Biosciences Inc (CTKB) - Total Liabilities
Based on the latest financial reports, Cytek Biosciences Inc (CTKB) has total liabilities worth $121.47 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cytek Biosciences Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Cytek Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. See Cytek Biosciences Inc (CTKB) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Cytek Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Cytek Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chularat Hospital Public Company Limited
BK:CHG
|
Thailand | ฿2.10 Billion |
|
Invesco California Value Muni Inc Tr
NYSE:VCV
|
USA | $318.74 Million |
|
Daou Data Corp
KQ:032190
|
Korea | ₩67.26 Trillion |
|
United States Cellular Corporation
NYSE:USM
|
USA | $2.38 Billion |
|
Sunrise Energy Metals Ltd
AU:SRL
|
Australia | AU$1.37 Million |
|
Capital Bancorp
NASDAQ:CBNK
|
USA | $3.40 Billion |
|
Symphony Limited
NSE:SYMPHONY
|
India | Rs6.34 Billion |
|
Si-Bone Inc
NASDAQ:SIBN
|
USA | $63.78 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Cytek Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cytek Biosciences Inc (CTKB) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cytek Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cytek Biosciences Inc (2019–2025)
The table below shows the annual total liabilities of Cytek Biosciences Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $119.80 Million | +15.46% |
| 2024-12-31 | $103.76 Million | +2.34% |
| 2023-12-31 | $101.39 Million | +7.95% |
| 2022-12-31 | $93.93 Million | +62.17% |
| 2021-12-31 | $57.92 Million | -75.46% |
| 2020-12-31 | $236.01 Million | +110.60% |
| 2019-12-31 | $112.06 Million | -- |
About Cytek Biosciences Inc
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies usin… Read more